跳至主要内容
临床试验/NCT03913377
NCT03913377已完成不适用

Ocular Characteristics in Contact Lens and Spectacle Wear

Johnson & Johnson Vision Care, Inc.5 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2019年4月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
78
试验地点
5
主要终点
Non-Invasive Break Up Time (NIBUT) or Non-Invasive Keratograph Break Up Time (NIKBUT)

研究概览

简要总结

This clinical study will investigate the difference in ocular characteristics between contact lens wear and spectacle wear among habitual contact lens wearers, using a 2-treatment by 2-period cross-over design. There will be a 1-week washout between the two study periods to eliminate any potential carryover effect.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 42 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:
  • The subject will have completed the pre-screening Classification questionnaire.
  • Subject must have a working cell phone capable of sending and receiving text messages.
  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Between 18 and 42 (inclusive) years of age at the time of screening
  • Be a current soft contact lens wearer in both eyes with a minimum of 5 days/week wear time over the last 1 month by self-report OR be a full-time spectacle wearer (7 days/ week) without contact lens wear over the last 6 months.
  • Subjects must be willing to adhere to spectacle-only refractive correction for approximately 1 week.
  • Subjects must possess a functional / usable pair of spectacles with which they can achieve 20/20 Snellen visual acuity or better at distance and near, and bring them to the visit
  • The subject's vertex corrected spherical distance refraction must be in the range (+/-0.25 D) of -2.00 D to -6.00 D (inclusive) in each eye.
  • The subject's vertex corrected refractive cylinder must be equal or less than -0.75 diopters in each eye.
  • Contact lens wearers must have spherical best corrected visual acuity of 20/25 or better in each eye.
  • Snellen visual acuity at distance and near must be within 1 line between subject's own spectacle and the manifest refraction, distance and near, OD & OS.

排除标准

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:
  • Currently pregnant or lactating, by self-report
  • Any ocular or systemic allergies, disease or use of medication which may interfere with contact lens wear and/or participation in the study (at the discretion of the investigator).
  • Any active ocular abnormalities/conditions that may interfere with contact lens wear and/or participation in the study (at the discretion of the investigator).
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear
  • Habitual contact lens wear modality as extended wear (≥1 night per month of extended wear).
  • Habitual contact lens is rigid gas permeable, toric, monovision or multi-focal
  • Habitual spectacle contains an add power, photochromic or tint.
  • Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.)
  • Participation in any contact lens or lens care product clinical trial within 2 weeks prior to study enrollment.
  • Employee or employee's immediate family member of clinical site (e.g., Investigator, Coordinator, Technician)
  • Current habitual use of Restasis, Xiidra, ocular steroids, or any medication (RX or OTC) that may interfere with contact lens wear and/or participation in the study (at the discretion of the investigator)
  • Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
  • Any Grade 3 or greater biomicroscopy findings (this includes, corneal edema, corneal staining, corneal vascularization, conjunctival injection, tarsal abnormalities, bulbar injection) on the FDA classification scale (CTP-2018).
  • Accommodative/binocular dysfunction, determined by study procedures.

结局指标

主要结局

Non-Invasive Break Up Time (NIBUT) or Non-Invasive Keratograph Break Up Time (NIKBUT)

时间窗: 1-Week Follow-up

NIBUT/NIKBUT was measured as the time interval in seconds after the final blink to the first appearance of distortion in the reflected rings; or to the time that the participant has to blink due to discomfort. NIBUT is measured by a topographer (e.g. Medmont) via observation by the investigator and a stopwatch. NIKBUTis measured by the Oculus Keratograph and reported by the instrument. Different instrumentation was used depending on site availability. Combined measurements of pre-lens data collected for the interventional arm are reported. Only the interventional arm was reported since the primary analysis was conducted among habitual contact lens users. The average NIKBUT was reported for each treatment. Higher values indicate better performance

次要结局

  • Total Scores of Meibomian Gland Expressibility (MGE)(1-Week Follow-up)
  • Conjunctival Staining(1-Week Follow-up)
  • Number of Eyes With Clinically Significant (Grade 3 or 4 of Overall Classification) Lid Wiper Epitheliopathy(1-Week Follow-up)
  • Meibomian Gland Expressibility (MGE) Grades(1-Week Follow-up)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验